BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian tells Proactive the firm is working towards becoming a pure-play biotechnology company by merging with privately-held Altum Pharmaceuticals Inc.
Doroudian says under the merger, BetterLife will acquire worldwide rights to commercialize and sell Altum's lead product AP-003, an inhalation formulation that could represent a potential treatment against the coronavirus.
Price: 0.8871 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...
Basic Materials
Health
Retail & consumer
Prev article
